Avery Therapeutics, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies

Avery Therapeutics is a preclinical-stage company developing advanced therapies for patients suffering from cardiovascular diseases. Avery’s lead candidate is an allogeneic tissue engineered cardiac graft, MyCardia™ in development for treatment of chronic heart failure. Using Avery’s proprietary manufacturing process, MyCardia can be manufactured at scale, cryopreserved, and shipped ready to use. Avery is leveraging its proprietary tissue platform to pursue other cardiovascular indications.


 


Avery Therapeutics, Inc. is presenting at part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Arizona
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
MyCardia™
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Avery Therapeutics, Inc.